Cervical cancer in early stage has a good prognosis and can be controlled with surgery or radiotherapy; retrospective and perspective studies have recently confirmed these results [1] . Primary radiotherapy with external beam and brachytherapy has until now been the reference treatment for locally advanced cancers (stages IB2-IVA). According to the data given in the last FIGO Annual Report [2] and by the radiation centers which published the best results [3, 5] , five-year survival ranges from 63% to 70% for stage I IB and from 16% to 25% for stage IVA. Pelvic failure occurs in two out of three relapsed patients, and the greater the frequency the greater the volume of the neoplasia. Unfortunately, stage IB2 is seen in a different group of patients with tumors >4 cm in diameter. In addition, the modalities of diameter evaluation are difficult to compare because of poor objectivity: digital clinical examination (with or without anesthesia), alginate mold, CT, MRI. It is also hard to compare the experiences reported in the literature; analogous considerations are of use for clinical stage IIB and stage I IIB while, by contrast, the staging for IIIA, I IIB (urologic) and IVA is objective.
Disease-free survival and survival are closely correlated to retroperitoneal disease, especially when it is macroscopically present in the para-aortic nodes [3] . Since the 1960s, simple hysterectomy after primary radiotherapy has been favored by some centers, but without agreement in the literature [3] [4] [5] [6] . Radiological and surgical staging before the planned radiotherapy was first applied in the 1970s, but it has yet to be unanimously approved. Moreover, staging modalites are different: nodal biopsy with extraperitoneal access, with intraperitoneal access by laparotomy or laparoscopy. These latest modalities make it possible to demonstrate intraperitoneal disease, most often represented by a tumor on the peritoneal surface of the abdominal cavity, closer tothe uterine isthmus, with or without extension to the contiguous organs.
Chemotherapy has been combined with radiotherapy in the treatment of locally advanced cervical cancer with nodal involvement in the attempt to reduce the rate of local failure and distant metastasis. The most promising results have been obtained with cisplatin (CDDP) and its derivatives such as carboplatin (CBDCA), 5-fluorouracil (5-FU), hydroxyurea (HU) and mitomicyn-C (MMC), used as single agents or in multidrug combination, showing a high activity, with rates of response that range from 20% to the 30%.
The rationale for the use of neoadjuvant chemotherapy to radiation is to reduce the size of the tumor before beginning radiotherapy. Unfortunately the residual tumor after chemotherapy may be composed by neoplastic cells resistant to the drugs as well as to radiation.
The probable advantages of a chemotherapy treatment concurrent with irradiation are numerous: synergistic action between the radiotherapy and the antineoplastic agents; lack of delay of the primary treatment; reduced possibility of induction of cross resistance; direct effect of the drugs on the local disease as well as on distant metastasis [7] .
The use of concomitant chemoradiation in phase II studies offers a local control ranging from 55% to 95%, with a survival of 25% to 63% [7, 8] .
Another option is to administer chemotherapy after radiation as a systemic adjuvant therapy, to consolidate the local result and to control subclinical disease outside the radiation fields. Such an approach has not been adequately explored as yet.
In his Editorial, published in 1998, Thigpen reports the evidence, based on preliminary data, of significant advantages of concurrent chemoradiation over radiation alone or sequential radio-chemotherapy [9] .
In February 1999 the NCI published a Clinical Announcement of the preliminary results of five controlled clinical studies (one of them for high-risk patients after radical surgery) conducted by NCI-sponsored Clinical Trial Cooperative Groups. This communication summarizes a significant survival advantage when the radiotherapy is administered concomitant with platinumbased chemotherapy. The results of the four studies of radical therapy strongly suggest better results with the concomitant chemo-radiation treatment.
GOG protocol #85, comparing radiotherapy and HU versus radiotherapy with 5-FU and cisplatin in 386 stages IIB-IVA patients (intraperitoneal and para-aortic nodal disease excluded) show a statistical significant difference in three-year survival (57% vs. 67%).
In RTOG protocol #9001, 389 patients with FIGO stages IIB and IVA, or stages IB and IIA with biopsyproven positive pelvic nodes or tumor size > 5 cm were treated with radiotherapy plus 5-FU and cisplatin vs. extended field external radiotherapy (pelvis and paraaortic). The three-year survival rate is 75% compared to 63%, and the difference is statistically significant.
In GOG protocol #120, 526 patients with FIGO Stages IIB, III and IVA and negative para-aortic nodes were randomly assigned to receive 1) radiotherapy, with weekly cisplatin vs. 2) radiotherapy with 5-FU, cisplatin, and HU, vs. 3) radiotherapy and HU.
The three-year survival rate for women on the radiotherapy plus cisplatin arm and the radiotherapy plus 5-FU, cisplatin, and HU arm is 65% compared to 47% for the radiotherapy plus HU arm. The difference is statistically significant.
A fourth randomized study (GOG protocol #123) shows, in stage IB bulky disease with negative pelvic and para-aortic nodes (radiologically and/or surgically determined), a significant difference in three-year survival rate after radiotherapy plus cisplatin followed by extrafascial hysterectomy vs. radiotherapy plus extrafascial hysterectomy (83% vs. 74%).
All studies agree that more complete data on followup for at least five years are needed (it is well-known that after primary radiotherapy late relapses are also possible). These more complete data could modify some of today's assumptions. It is clear that the agreement of the results in these studies constitutes a rare event in the treatment of human solid tumors, so rare in fact that the NCI decided to anticipate the publication of the data, emphasizing that the contention in the NIH Consensus Statement on Cervical Cancer in 1996 that "there is no evidence that hydroxyhurea or any other concomitant chemotherapy agent should be incorporated into standard practice" should be reconsidered, and stating that "strong consideration should be given to incorporation of concurrent cisplatin-based chemotherapy with radiation therapy in women who require radiation therapy for treatment of cervical cancer." Another strong affirmation included in the document is that "The GOG, RTOG and SWOG trials highlight the importance of randomized clinical trials to cancer medicine."
All four of these studies concern locally advanced disease, but some patients with negative prognostic factors such as para-aortic lymph node involvement or tumor on the peritoneal surface of the abdominal cavity have been excluded. In addition, it is well known that surgical staging by an extra-or intra-peritoneal approach involves a further selection of patients in relation to age, anatomy and general condition. Moreover, all of this may help explain the small number of patients recruited per year per center. It remains difficult to compare these studies with others published in the literature in which the only selection criteria has been stage.
It is not possible to foresee the positive or negative impact of these selection criteria should this treatment modality be applied to all patients with locally advanced cervical cancer. These studies, however, represent the data with which new prospective controlled innovative trials will be compared.
